GlaxoSmithKline ( GB:GSK ) has released an update. GlaxoSmithKline (GSK) has initiated an appeal process against the Delaware Superior Court's decision regarding the admissibility of expert testimony in the Zantac litigation, asserting that the ruling misapplies the established Daubert standard. GSK, along with Pfizer, Sanofi, and Boehringer Ingelheim, is seeking an interlocutory review by the Delaware Supreme Court due to the significant implications of this ruling for businesses incorporated in Delaware. Despite the legal challenges, GSK maintains that scientific studies support their stance that ranitidine does not increase cancer risk.